A Study Comparing Bevacizumab Therapy With or Without Erlotinib for First-Line Treatment of Non-Small Cell Lung Cancer (ATLAS)
This study is ongoing, but not recruiting participants.
Sponsor:
Genentech
Information provided by (Responsible Party):
Genentech
ClinicalTrials.gov Identifier:
NCT00257608
First received: November 21, 2005
Last updated: December 6, 2011
Last verified: December 2011
Tracking Information | |||||
---|---|---|---|---|---|
First Received Date ICMJE | November 21, 2005 | ||||
Last Updated Date | December 6, 2011 | ||||
Start Date ICMJE | January 2006 | ||||
Estimated Primary Completion Date | December 2012 (final data collection date for primary outcome measure) | ||||
Current Primary Outcome Measures ICMJE |
Progression-free survival [ Time Frame: Post-chemo phase ] [ Designated as safety issue: No ] | ||||
Original Primary Outcome Measures ICMJE |
To compare progression free survival (PFS) in subjects randomized to bevacizumab+erlotinib versus bevacizumab+erlotinib placebo in subjects with non squamous non-small cell lung cancer (NSCLC). | ||||
Change History | Complete list of historical versions of study NCT00257608 on ClinicalTrials.gov Archive Site | ||||
Current Secondary Outcome Measures ICMJE |
|
||||
Original Secondary Outcome Measures ICMJE |
To evaluate the safety of bevacizumab during the chemotherapy phase by chemotherapy regimen and overall; to evaluate the safety of bevacizumab+erlotinib versus bevacizumab+erlotinib-placebo. | ||||
Current Other Outcome Measures ICMJE | |||||
Original Other Outcome Measures ICMJE | |||||
Descriptive Information | |||||
Brief Title ICMJE | A Study Comparing Bevacizumab Therapy With or Without Erlotinib for First-Line Treatment of Non-Small Cell Lung Cancer (ATLAS) | ||||
Official Title ICMJE | A Randomized, Double-Blind, Placebo-Controlled, Phase IIIb Trial Comparing Bevacizumab Therapy With or Without Erlotinib After Completion of Chemotherapy With Bevacizumab for the First-Line Treatment of Locally Advanced, Recurrent, or Metastatic Non-Small Cell Lung Cancer | ||||
Brief Summary | This is a Phase IIIb, multicenter, randomized, placebo-controlled trial to evaluate the safety and efficacy of chemotherapy+bevacizumab followed by bevacizumab+erlotinib versus bevacizumab+erlotinib placebo in subjects with locally advanced or metastatic NSCLC. |
||||
Detailed Description | |||||
Study Type ICMJE | Interventional | ||||
Study Phase | Phase 3 | ||||
Study Design ICMJE | Allocation: Randomized Intervention Model: Parallel Assignment Masking: Double Blind (Subject, Investigator) Primary Purpose: Treatment |
||||
Condition ICMJE | Non-Small Cell Lung Cancer | ||||
Intervention ICMJE |
|
||||
Study Arm (s) |
|
||||
Publications * | |||||
* Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline. |
|||||
Recruitment Information | |||||
Recruitment Status ICMJE | Active, not recruiting | ||||
Estimated Enrollment ICMJE | 1150 | ||||
Estimated Completion Date | December 2012 | ||||
Estimated Primary Completion Date | December 2012 (final data collection date for primary outcome measure) | ||||
Eligibility Criteria ICMJE | Inclusion Criteria:
Exclusion Criteria:
|
||||
Gender | Both | ||||
Ages | 18 Years and older | ||||
Accepts Healthy Volunteers | No | ||||
Contacts ICMJE | Contact information is only displayed when the study is recruiting subjects | ||||
Location Countries ICMJE | United States, Argentina, Australia, Belgium, Brazil, Bulgaria, Hong Kong, Israel, Italy, Mexico, Philippines, Romania, Singapore, Spain, Taiwan, Thailand, United Kingdom | ||||
Administrative Information | |||||
NCT Number ICMJE | NCT00257608 | ||||
Other Study ID Numbers ICMJE | AVF3671g | ||||
Has Data Monitoring Committee | |||||
Responsible Party | Genentech | ||||
Study Sponsor ICMJE | Genentech | ||||
Collaborators ICMJE | |||||
Investigators ICMJE |
|
||||
Information Provided By | Genentech | ||||
Verification Date | December 2011 | ||||
ICMJE Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP |